This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Amarin Rises on Priority Review for Vascepa Label Expansion
by Zacks Equity Research
Amarin's (AMRN) label expansion application for hypertriglyceridemia drug, Vascepa, gets priority review from the FDA.
Merck (MRK) Up This Year So Far: Will the Momentum Continue?
by Kinjel Shah
Merck's shares are up 6.2% this year so far on strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.
Biotech Stock Roundup: AMGN's Nuevolution Buyout, CELG, INCY Drugs' Label Expansion
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Amgen (AMGN) Offers to Acquire Drug Discovery Platform
by Zacks Equity Research
Amgen (AMGN) looks to acquire Nuevolution in an all-cash deal. Nuevolution focuses on discovering small molecule drugs partnering its proprietary platform.
Ligand Grants Preclinical Candidate Rights to UK-based Firm
by Zacks Equity Research
Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.
AbbVie Settles Humira Litigation With Boehringer Ingelheim
by Zacks Equity Research
AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.
Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer
by Zacks Equity Research
Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.
The Zacks Analyst Blog Highlights: Amgen, Altria, Booking, General Motors and Occidental
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, Altria, Booking, General Motors and Occidental
Top Stock Reports for Amgen, Altria & Booking Holdings
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), Altria (MO) and Booking Holdings (BKNG).
Radius (RDUS) Posts Narrower Q1 Loss, Misses on Revenues
by Zacks Equity Research
Radius Health (RDUS) posts narrower-than-expected Q1 loss but Tymlos sales disappoint.
Biotech ETFs in Focus on String of Q1 Earnings Beats
by Sweta Jaiswal, FRM
Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.
Allergan (AGN) Beats on Q1 Earnings & Sales, Raises '19 View
by Zacks Equity Research
Allergan's (AGN) stock declines slightly in pre-market trading despite the company delivering earnings and revenue beat in the first quarter while marginally raising its guidance
Ligand (LGND) Q1 Earnings & Sales Fall Y/Y, Stock Down
by Zacks Equity Research
Ligand (LGND) first-quarter earnings and sales decrease year over year.
Teva (TEVA) Q1 Earnings Beat, Copaxone Drags Sales Down
by Zacks Equity Research
Teva Pharmaceutical (TEVA) beats estimates for earnings but misses the same for sales. Blockbuster drug Copaxone sales continue to erode amid generic competition.
Protalix (PLX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Protalix (PLX) is scheduled to release its first quarter 2019 results on May 6 and we expect the company to provide updates on the pipeline.
Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates
by Zacks Equity Research
Key highlights of the past week are earnings releases by most leading biotech entities.
Can Allergan (AGN) Beat Earnings Estimates Again in Q1?
by Zacks Equity Research
Allergan's (AGN) key products like Botox are likely to provide top-line support in Q1 as loss of exclusivity of several products hurts sales
Amgen (AMGN) Q1 Earnings Top, Sales Hurt by Pricing Pressure
by Zacks Equity Research
Amgen (AMGN) earnings beat estimates in the first quarter while sales come in line with the same. The company raises the lower end of its previously issued sales and earnings guidance for 2019.
Lilly (LLY) Down Despite Q1 Earnings Beat on Sales View Cut
by Zacks Equity Research
Eli Lilly's (LLY) earnings beat estimates in Q1. Stock falls in pre-market trading as the company lowers its full-year revenue forecast.
Pfizer (PFE) Beats on Q1 Earnings & Sales, Raises EPS View
by Zacks Equity Research
Pfizer (PFE) beat estimates for first-quarter earnings and sales and raised the mid-point of its earnings expectations for 2019 by a penny and confirmed its previous outlook for full-year sales.
Teladoc (TDOC) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Teladoc's (TDOC) Q1 earnings should benefit from increase in revenues, partly offset by rise in expenses.
Is a Beat in Store for Cigna (CI) This Earnings Season?
by Zacks Equity Research
Cigna's (CI) Q1 earnings should benefit from increase in revenues and membership.
Why Amgen (AMGN) Might Surprise This Earnings Season
by Zacks Equity Research
Amgen (AMGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Raises EPS View
by Zacks Equity Research
AbbVie (ABBV) beats first-quarter estimates for both earnings and revenues. Biosimilar competition impacts Humira sales in ex-U.S. markets. Growth in Imbruvica sales offsets Humira decline.
Pfizer (PFE) to Report Q1 Earnings: Will It Beat Estimates?
by Kinjel Shah
While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and weak sales in the EH segment will hurt.